Reducing In-Stent Restenosis through Novel Stent Flow Field Augmentation by Murphy, Eoin & Boyle, Fergal
Technological University Dublin 
ARROW@TU Dublin 
Articles Biomedical Devices and Assistive Technology Research Group 
2012-12-01 
Reducing In-Stent Restenosis through Novel Stent Flow Field 
Augmentation 
Eoin Murphy 
Technological University Dublin, eoin.murphy@tudublin.ie 
Fergal Boyle 
Dublin Institute of Technology, fergal.boyle@tudublin.ie 
Follow this and additional works at: https://arrow.tudublin.ie/biodevart 
 Part of the Biomedical Engineering and Bioengineering Commons 
Recommended Citation 
Murphy, E., Boyle, F. (2012) Reducing in-stent restenosis through novel stent flow field augmentation. 
Cardiovascular Engineering and Technology, Vol. 3, no. 4, pp. 353-373. doi:10.1007/s13239-012-0109-3 
This Article is brought to you for free and open access by 
the Biomedical Devices and Assistive Technology 
Research Group at ARROW@TU Dublin. It has been 
accepted for inclusion in Articles by an authorized 
administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
1 Reducing In-Stent Restenosis Through Novel Stent Flow
2 Field Augmentation
3
4 EOIN A. MURPHY and FERGAL J. BOYLE
5 Department of Mechanical Engineering, Dublin Institute of Technology, Bolton Street, Dublin 1, Ireland
6 (Received 30 May 2012; accepted 25 September 2012)
7 Associate Editor Bruce H. KenKnight oversaw the review of this article.
8
9 Abstract—In-stent restenosis (ISR), manifested as a
10 re-narrowing of the arterial lumen post-implantation of a
11 stent, is a detrimental limitation of stent technology. Under-
12 standing and consequently devising ways of reducing the
13 frequency of ISR has been a continuing goal of research into
14 improved stent designs. The biological processes that can
15 lead to ISR have been found to be partially flow dependent
16 with the local hemodynamics at the arterial wall of crucial
17 importance. This paper investigates these biological processes
18 and their instigating factors. Furthermore, the history and
19 theory behind three stent technologies which endeavour to
20 reduce ISR rates through stent flow field augmentation are
21 presented: a flow divider which increases the blood-flow
22 velocity and consequently the wall shear stress through a
23 stented region, and two novel stent technologies which
24 induce helical flow that mimics the natural blood flow present
25 in healthy arteries. This paper serves as a thorough intro-
26 duction to both the investigation of ISR, particularly the
27 influence of the local hemodynamics, and to the three novel
28 stent technologies which aim to reduce ISR rates.
29 Keywords—In-stent restenosis, Wall shear stress,
30 Helical flow, Flow divider, Helical stent, Helical-ridge insert.
31
323 INTRODUCTION
34 Cardiovascular disease (CVD) is currently one of
35 the leading causes of death in the developed world. In a
36 report published by the American Heart Association
37 (AHA) in February 2011 it was stated that CVD
38 accounted for 33.6% (813,804) of all 2,243,712 deaths
39 in the US in 2007.114 CVD encompasses a spectrum of
40 diseases which affect the cardiovascular system
41 including hypertension, stroke and coronary artery
42 disease (CAD). CAD accounted for 49.9% of all
43deaths due to CVD in the US in 2007.114 In cases of
44CAD, atherosclerotic lesions, typically formed in the
45coronary arteries over the course of decades, narrow
46the arterial lumen area, thereby reducing the flow of
47blood, and consequently oxygen and nutrients, to tis-
48sue cells downstream.
49Balloon angioplasty was developed by Charles
50Dotter in the 1960s31 as a minimally invasive treatment
51for the arterial narrowing caused by atherosclerotic
52lesions in the peripheral arteries, and later in the 1970 s
53it was applied to renal, coronary and iliac arteries by
54Gru¨ntzig and co-workers.49–51 Re-blockage of a trea-
55ted coronary artery following this procedure, known as
56restenosis, was reported in 30–60% of patients,44 with
57these patients consequently needing re-treatment with
58either percutaneous methods or bypass surgery.
59Restenosis following balloon angioplasty is attributed
60to three key responses: acute elastic recoil, negative
61wall remodelling (reduction in lumen area without a
62change in wall mass) and arterial wall thickening into
63the lumen (due to an increase in the number of cells
64within the arterial wall).
65Bare metal stents (BMS) were incorporated into the
66angioplasty procedure in the 1990s to serve as a rigid
67scaffold, thus eliminating elastic recoil and reducing
68wall remodelling,56 with some cases of positive
69remodelling reported.102 Even though stenting reduced
70restenosis rates to between 22 and 32%,37,44,126 it still
71continued to be a burden. Restenosis with stents,
72known as in-stent restenosis (ISR), is mostly due to
73arterial wall thickening. Understanding and conse-
74quently devising ways of reducing the frequency of ISR
75has been a continuing goal of research into improved
76stent designs. From this research drug-eluting stents
77(DES) were developed which use anti-proliferative,
78immunosuppressive, pro-healing and anti-inflamma-
79tory drugs in an attempt to prevent ISR. DESs have
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80 proved effective, with ISR rates at six-month follow-up
81 as low as 2.6–10.1%137 and consequently DESs sur-
82 passed BMSs as the preferred stent choice with 70–80%
83 of stent procedures in the US carried out with DESs by
84 mid-2009.41,78 However, ISR is still a problem along
85 with stent thrombosis, and delayed re-endothelialisa-
86 tion (re-growth of the endothelium) due to the anti-
87 proliferative properties of some DES drugs.42
88 Newer stents currently in development or
89 undergoing clinical trials are predominantly variations
90 of the DES design with perceived improvements, such
91 as biodegradable polymer and polymer-free coatings,
92 novel coatings which encourage re-endothelialisation,
93 and completely biodegradable platforms.60,97 How-
94 ever, there are other ideas for reducing ISR which are
95 beginning to show promise which use the fact that the
96 biological healing response to stent implantation is
97 partially dependent on the local hemodynamics in the
98 stented artery. With this in mind, this paper has two
99 major aims: one is to investigate the biological pro-
100 cesses leading to ISR with particular emphasis on how
101 the local hemodynamics influence these processes and
102 the second is to review three devices which augment the
103 local hemodynamics in an attempt to reduce ISR rates.
104 The devices reviewed are a flow divider which increases
105 the blood-flow velocity and consequently the wall
106 shear stress (WSS) through a stented region, and two
107 novel stents which endeavour to elicit helical flow,
108 mimicking physiological blood flow, within and distal
109 to the stented region. This paper clearly highlights the
110 quality of the stent flow field as an important design
111 consideration, and the three devices reviewed show
112 how its augmentation can, in theory, be employed to
113 reduce ISR rates. A complete review of these devices
114 has not been published in the literature before.
115 ‘‘In-Stent Resteno’’ section investigates the effects of
116stent implantation and how these can lead to ISR
117through the biological processes they instigate in the
118arterial wall. ‘‘Flow-Augmentation Stent Devic’’ sec-
119tion reviews the history and theory behind the three
120stent flow field augmentation devices, followed by a
121discussion and conclusions in ‘‘Discussion’’ and
122‘‘Conclusion’’ sections, respectively.
123IN-STENT RESTENOSIS
124Introduction
125A diagram of a healthy arterial wall is given in
126Fig. 1; however, the exact composition of a diseased
127artery deviates from this ideal form. Stent implantation
128has three effects on a treated artery: it induces struc-
129tural injury, introduces a foreign body and alters the
130local hemodynamics. These three effects instigate and
131influence four interacting biological processes which
132can lead to re-narrowing of the stented artery, known
133as ISR. ISR is defined as angiographic evidence of a
134loss of greater than 50% of the lumen diameter post
135intervention.95
136Structural injury is inflicted on the arterial wall
137during the implantation procedure. The stent and
138balloon denude most of the endothelium on contact,
139exposing the underlying collagen fibres and leaving
140some damaged endothelial cells (ECs) directly adjacent
141to the stent struts.116 Stent implantation stretches, and
142therefore stresses, the arterial wall and as a result the
143cellular structure of vascular smooth muscle cells
144(VSMCs) present in the media can be disrupted, and
145the internal elastic lamina (IEL) and the media can
146rupture. Atherosclerotic lesions present at an implan-
147tation site are inelastic and frequently split rather than
Media
Adventitia
IEL
EEL
EC
Collagen Fibres
Fibroblast
Connective Tissue
VSMC
Arterial
Lumen
Intima
Extracellular Matrix
Elastin
FIGURE 1. Simplified diagram of a healthy artery showing the separate layers and the main cellular components and fibres.
Abbreviations: internal elastic lamina (IEL), external elastic lamina (EEL), endothelial cell (EC) and vascular smooth muscle cell
(VSMC).
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148 stretch upon stent implantation. This combined dam-
149 age induces a healing response within the arterial wall.
150 When a stent is inserted in the artery its non-
151 biological surface composition induces a foreign-body
152 response. This response is dependent on properties such
153 as the biocompatibility of the surface material and the
154 surface roughness, along with the existence of contam-
155 inants on the surface of the stent. The surface material
156 and roughness of a stent affects how quickly the arterial
157 wall heals over the struts. Contaminants, such as powder
158 from surgical gloves, have been found on a stent surface
159 due to handling before catheter insertion.4 Improved
160 biocompatibility of stent materials and rinsing of stents
161 before implantation reduce the foreign-body response;
162 however, the non-biological nature of stents instigates
163 cells and proteins in the body to react to what they
164 perceive as a foreign invader.
165 When a stent is implanted in a diseased artery the
166 geometry of the artery is altered, which in turn aug-
167 ments the local hemodynamics. The lesion is com-
168 pressed out against the arterial wall, clearing the lumen
169 blockage and reinstating blood flow. The stented
170 artery adopts a new geometry based on the stent strut
171 configuration with the struts pressed against the arte-
172 rial wall and prolapsed tissue between them. In some
173 cases of over-inflation of the balloon, a step-up phe-
174 nomenon at the ends of the stent can occur, creating
175 recirculation zones at these points. Also, some degree
176 of longitudinal straightening by stent implantation has
177 been reported in curved arteries.52 These changes are a
178 deviation from the smooth surface presented to the
179 blood flow by a healthy artery and lead to disturbed
180 flow within the stented artery. This disturbed flow can
181 encompass flow separation and reattachment, stagna-
182 tion and recirculation zones, long particle residence
183 times, low and high shear stress (SS) within the blood
184 flow, low and high WSS zones, oscillatory WSS, and
185 high WSS gradient (WSSG) and angle gradient
186 (WSSAG). Cellular components of the arterial wall are
187 impelled to respond to this augmentation of the local
188 hemodynamics in order to return the artery to a cir-
189 cular lumenal cross-section with smooth walls. Also,
190 some of the changes in the local hemodynamics are not
191 conducive to the natural healing of the arterial wall
192 and instead hinder or adversely affect it, which con-
193 sequently can lead to ISR.
194 The four interacting biological processes, instigated
195 by these three effects of stent implantation, are
196 thrombus formation, inflammation, neointimal
197 hyperplasia (NIH) and re-endothelialisation. These
198 biological processes, their interactions and the influ-
199 ences of the three instigators on each are described in
200 the following sections, along with a review of the
201 effects of stent design on these instigators and biolog-
202 ical processes.
203Thrombus Formation
204Thrombus formation, in general, is the body’s
205emergency response mechanism to structural injury
206and entails primary and secondary haemostasis. Pri-
207mary haemostasis involves blood-borne platelets
208quickly adhering to form a plug at an injury site.
209Occurring in parallel with this is secondary haemo-
210stasis which involves the formation of fibrin fibres
211through the coagulation cascade, and these fibrin fibres
212bind the adhered platelets together at the injury site.
213When structural injury is inflicted on an artery by
214stent implantation, platelets present in the bloodstream
215are activated by exposed collagen and plaque, and by
216proteins expressed by damaged ECs (e.g., fibronectin
217and von Willebrand factor (vWf)). Activated platelets
218are more sensitive to chemical signals and adhere to the
219collagen, plaque and proteins on the arterial wall,
220changing their cytoskeleton (cell scaffolding) to
221become more flexible and capable of spreading out
222over the injury site. Activated platelets also release
223platelet activating factor (PAF), adenosine diphos-
224phate (ADP) and thromboxane A2 into the blood-
225stream which in turn activate more platelets and aid in
226the aggregation of platelets at an injury site. The
227coagulation cascade involves several coagulation fac-
228tors present in the bloodstream and those released by
229adhered platelets and leukocytes, and VSMCs (e.g.,
230tissue factor). Through the coagulation cascade pro-
231thrombin, present in the blood plasma, is converted to
232thrombin which both activates more platelets and
233causes soluble fibrinogen molecules in the blood plas-
234ma to convert into fibrin monomers. These fibrin
235monomers form fibrin fibres that bind the platelets that
236have aggregated together at the injury site, forming a
237thrombus.
238In addition to this response to structural injury,
239thrombus formation is also initiated by the presence of
240a foreign body. Blood-soluble proteins adsorb onto the
241stent surface, forming a thin film which provides a
242provisional matrix that controls the subsequent bio-
243logical processes of the foreign-body response.1 Dif-
244ferent proteins (e.g., albumin, fibrinogen, fibronectin,
245vitronectin and y-globulin) adsorb onto the stent sur-
246face depending on the properties of the surface mate-
247rial.1 These adsorbed proteins produce different
248effects; fibrinogen for example is pro-thrombotic,
249promoting activation and adhesion of platelets,
250whereas albumin reduces platelet adhesion and aggre-
251gation.85 Fibrinogen is adsorbed preferentially over
252other proteins on many surfaces, especially polymers,85
253and thus facilitates thrombus formation at a stent
254implantation site.
255Thrombus formation has been found to be heavily
256flow dependent. The platelets, coagulation factors and
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257 chemical substances involved in thrombus formation
258 are predominantly blood-borne particles and as such
259 their movements are dictated by the local hemody-
260 namics. High particle residence times at the injury site
261 facilitate increased platelet exposure times to throm-
262 botic arterial wall components and activating chemical
263 substances. This increased exposure time results in a
264 greater probability of platelet activation2 with
265 enhanced platelet activation being observed in low flow
266 conditions.2 Increased platelet adhesion has been
267 observed downstream of recirculation zones, where the
268 main flow reattaches to the arterial wall, due to the
269 convection of platelets towards the arterial wall.33,124
270 Red blood cells (RBCs) can also get trapped by fibrin
271 monomers in the thrombus within recirculation zones
272 or other low SS regions. Also, in regions of low WSS
273 (<10–12 dyne/cm2) ECs respond by down-regulating
274 the release of anti-thrombotic agents and up-regulating
275 the expression of pro-coagulant and pro-thrombotic
276 agents, thus also instigating thrombus formation. High
277 SS within the blood flow can also activate platelets
278 depending on the magnitude of the SS and the expo-
279 sure time of platelets to this high SS.13 Figure 2 shows
280 the cells (platelets, RBCs and ECs), pro-thrombotic
281 agents and proteins involved in thrombus formation.
282 Inflammation
283 Inflammation involving leukocytes (e.g., lympho-
284 cytes, monocytes/macrophages, neutrophils, eosino-
285 phils and basophils) is the body’s primary defence
286 mechanism against infection. Leukocytes are attracted
287 to an injury site in order to prevent the spread of the
288tissue damage and infection, and to aid in wound
289healing and tissue repair.94
290Structural injury to the arterial wall by stent
291implantation triggers the expression of several cell
292adhesion molecules which mediate four steps, shown in
293Fig. 3, that each leukocyte undergoes in order to
294infiltrate an injury site. These four steps are the initial
295contact (tethering), leading to rolling and activation of
296the leukocyte, followed by firm adhesion and finally
297transmigration into the arterial wall. Tethering and
298rolling are mediated by cell adhesion molecules
299P-selectin (expressed by adhered platelets and damaged
300VSMCs) and E-selectin (expressed by damaged ECs)
301which interact with ligands expressed on the leukocyte
302surface. Firm adhesion is mediated by platelet glyco-
303protein (GP) Ib-b, vascular cell adhesion molecule 1
304(VCAM-1) and intercellular adhesion molecule 1
305(ICAM-1) expressed on the damaged wall, which
306interact with integrins expressed on the surface of the
307leukocytes, e.g., macrophage-1 antigen (MAC-1). The
308final step is driven by concentration gradients of che-
309mokines (chemotactic cytokines) released by damaged
310ECs and VSMCs, and by the leukocytes already pres-
311ent at the injury site. Neutrophil infiltration of the
312injury site represents the initial acute phase of the
313inflammatory response and they are present up to, but
314not beyond, 30 days after BMS implantation.36 The
315chronic phase of the inflammatory response involving
316lymphocyte and monocyte infiltration of the injury
317site, extends from 3 days to beyond 6 months for
318BMSs.36 When monocytes migrate across the platelet/
319fibrin thrombus to the site of initial injury, they dif-
320ferentiate into macrophages. These cells consume the
Stent Strut
Damaged ECs:
Fibronectin
vWf 
Exposed 
Collagen
Activated Platelet:
Thromboxane A2, 
ADP, PAF
Fibrin
Fibres
Adsorbed Protein Film
Trapped
RBC
FIGURE 2. Diagram showing the cells, pro-thrombotic agents and proteins involved in thrombus formation at an injury site
around a stent strut.
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321 damaged cells around the injury site and also secrete
322 interleukins which attract more leukocytes to the area.
323 The thin layer of proteins adsorbed onto the
324 implanted stent surface not only mediates the adhesion
325 of platelets, but also controls the inflammatory phase
326 of the foreign-body response to the stent. The com-
327 plement system, which consists of more than 20 plas-
328 ma-based proteins, is a primary contributor to the
329 innate immune system and is activated by the adsorbed
330 protein layer. Activation of the complement system
331 promotes the formation of enzymes and binding pro-
332 teins which regulate the inflammatory response to a
333 foreign body. Leukocytes, particularly neutrophils and
334 monocytes, follow increased concentration gradients
335 of chemo-attractant anaphylatoxins, such as C5a,
336 which are fragments produced by activation of the
337 complement system. Other products of complement
338 activation, such as C3b and iC3b, through a process
339 called opsonisation mark foreign particles for phago-
340 cytic removal (ingestion) by leukocytes and subsequent
341 proteolysis (digestion) by proteases (cellular enzymes).
342 This is the case for any contaminants on the stent
343 surface; however, in the case of a relatively large for-
344 eign body, such as a stent, which cannot be ingested,
345 adhered neutrophils and monocytes undergo a frus-
346 trated phagocytosis whereby they release their array of
347 potent oxygen metabolites and proteolytic enzymes.46
348 This can lead to an unresolved chronic inflammatory
349 response exemplified by the increased fusion of mac-
350 rophages into foreign body giant cells around an
351 implanted stent. Platelets which adhere to the adsorbed
352 protein layer on stent struts also release P-selectin to
353 aid leukocyte adhesion and these adhered leukocytes
354 can also encourage thrombus formation through
355elevated expression of tissue factor.35 Products of the
356complement system can interact with proteins involved
357in thrombus formation and thus, can also regulate
358each other. Metallic stent struts or the presence of a
359polymer coating on a stent can induce an allergic
360inflammatory reaction in some people, which is
361observed as eosinophil activation and presence at the
362implantation site.105
363The local hemodynamics can also mediate the
364adhesion of leukocytes at an implantation site. With
365increased thrombus formation due to the hemody-
366namics in certain regions, e.g., re-attachment areas
367where flow is directed towards the arterial wall, there is
368a greater amount of cell adhesion molecules available
369to capture passing leukocytes. In addition to this, it has
370been found that local vascular hemodynamics can
371affect leukocyte ligand expression,40, shape23 and
372consequently interaction with other cells.142 Leuko-
373cyte-EC interaction is heavily influenced by the local
374hemodynamics which becomes more relevant as the
375endothelium reforms over the implantation site. For
376instance, leukocytes retract their pseudopodia (tem-
377porary projections from leukocytes used to adhere to a
378surface) when exposed to nitric oxide (NO),96 which is
379produced by functioning ECs in response to physio-
380logical WSS (15 dyne/cm2).14 However, when ECs
381are exposed to low WSS (<10–12 dyne/cm2) or dis-
382turbed flow they decrease their expression of anti-
383inflammatory mediators (e.g., NO) and upregulate cell
384adhesion molecules (e.g., E-selectin, VCAM-1 and
385ICAM-1). Therefore, the establishment of normal
386physiological blood flow within a stented artery fol-
387lowing the procedure is crucial to avoiding prolonged
388inflammation and consequently possible ISR.
Stent Strut
Tethering Rolling
Firm Adhesion
Transmigration
Activated Platelets:
P-selectin, GPIb-
Damaged ECs:
E-selectin
Damaged VSMCs:
P-selectin
α
FIGURE 3. Diagram showing the four steps leukocytes undergo in order to infiltrate the injury site.
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389 Neointimal Hyperplasia
390 NIH takes place up to 18 months post-implanta-
391 tion, results in a thickening of the intimal layer, and is
392 the main cause of ISR. NIH involves the migration
393 and proliferation of VSMCs originating in the media,
394 and also differentiating from fibroblasts in the adven-
395 titia and bone-marrow-derived stem cells in the
396 bloodstream. In addition, the VSMCs synthesise
397 extracellular matrix (ECM). The degree of NIH is
398 heavily influenced by the degree of thrombus forma-
399 tion and inflammation which takes place at an
400 implantation site.
401 Damaged ECs and VSMCs, adhered leukocytes and
402 platelets release cytokines (proteins used for intercel-
403 lular communication) and mitogens (proteins which
404 encourage a cell to commence the cell-division cycle)
405 which encourage NIH at an injury site. The migration
406 of the VSMCs is stimulated by cytokines [e.g., tumor
407 necrosis factor (TNF) and interleukin-1 (IL-1)] released
408 by macrophages and also by some of the mitogens (e.g.,
409 platelet-derived growth factor (PDGF)). PDGF is
410 capable of stimulating migration at a much lower
411 concentration level than that needed for cell division48
412 and therefore, migration is an earlier response than
413 proliferation. In order for migration to occur enzymes
414 [e.g., matrix metalloproteinase (MMP)-9] released by
415 adhered leukocytes and VSMCs help in the dissolution
416 of the IEL and the existing ECM. This dissolution,
417 along with the disruption to the ECM caused by stent
418 implantation, allows the medial VSMCs and myofi-
419 broblasts (activated fibroblasts) to migrate through to
420 the neointimal region of the arterial wall. The prolif-
421 eration of VSMCs is instigated by mitogens [e.g.,
422 serotonin, thromboxane A2, PDGF and basic fibro-
423 blast growth factor (bFGF)] which are released by
424 damaged ECs and VSMCs, adhered leukocytes and
425 platelets. This proliferation produces a greater amount
426 of neointimal cells than does migration. In addition to
427 VSMC migration and proliferation, inflammatory and
428 hematopoietic cytokines [e.g., granulocyte colony-
429 stimulating factor (G-CSF)] produced by ECs and
430 leukocytes at the injury site mobilise stem cells from the
431 bone marrow to enter the bloodstream.68,69 These stem
432 cells can differentiate into smooth muscle progenitor
433 cells (SPCs), which adhere to fibronectin and differen-
434 tiate into VSMC-like cells in the presence of PDGF-BB
435 (a PDGF isoform) at the injury site.53,131 The stretching
436 of the original VSMCs in the arterial wall stimulates
437 them to synthesise collagen, a component of ECM,
438 which may serve to alleviate the additional stress
439 caused by stent implantation, but also increases the
440 overall wall volume.84 This, along with the synthesis of
441 ECM by neointimal VSMCs can contribute up to 80%
442 of the resultant wall thickening.44
443Leukocytes and platelets attracted to a foreign body
444can also release cytokines and mitogens which
445encourage NIH. Macrophages activated by biomedical
446polymers in vitro have been shown to stimulate fibro-
447blast activity.1 In addition to this, macrophages and
448foreign-body giant cells on a biomaterial surface
449modulate ECM fibrosis. This results in the formation
450of a fibrous capsule, mainly comprised of collagen
451fibres and leukocytes, which isolates the stent from the
452surrounding tissue and blood.1
453NIH can also be induced and influenced by local
454hemodynamics within the stented arterial region.
455Where local hemodynamics cause increased thrombus
456formation and inflammation, due to the release of
457mitogens by adhered leukocytes and platelets, this
458subsequently induces increased NIH. In regions where
459the endothelium has been denuded and the IEL dam-
460aged by stent implantation, underlining VSMCs may be
461exposed and affected by the local hemodynamics.
462Human VSMCs exposed to physiological or high WSS
463(14 and 28 dyne/cm2 respectively) for 24 h show an
464increase in transforming growth factor (TGF)-1 expres-
465sion which inhibits their proliferation, in comparison
466with a static control.148HighWSS (>15 dyne/cm2) also
467stimulates the release of stored mitogens (PDGF and
468bFGF) within VSMCs into the bloodstream while low
469WSS increases VSMC susceptibility to these mito-
470gens.135 Thus, in a stented artery where there is vari-
471ability between high and low WSS across the stent and
472arterial wall, increased proliferation would occur in low
473WSS zones.101 In addition, pulsatile turbulent WSS has
474also been found to stimulate VSMC proliferation,129
475and murine VSMCs exposed to steady laminar WSS of
47615 dyne/cm2 have been found to transdifferentiate into
477ECs.152 Within the arterial wall, VSMCs and myofi-
478broblasts are exposed to transmural interstitial shear
479stress which can be increased by endothelium denuda-
480tion, activating these cells and promoting their migra-
481tion into the intima or wound site.127 ECs present in the
482stented region downregulate anti-proliferative gene
483expression and upregulate the release of VSMC growth
484factors in response to lowWSS.14 The oxygen flux from
485the blood into the arterial wall, which is also heavily
486flow dependent, has also been found to influence
487VSMC behaviour. NIH has been found to be reduced
488in rabbits treated with supplemental oxygen,83 and
489areas of lowWSS where the oxygen flux into the arterial
490wall is low are hypothesised to experience increased
491NIH.144
492Re-Endothelialisation
493The endothelium fulfils several important physio-
494logical functions which include acting as a selective
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495 permeability barrier, participation in cardiovascular
496 homeostasis and inflammatory responses, regulation of
497 cellular growth and proliferation within the arterial
498 wall, angiogenesis and tumour metastasis.121 Consid-
499 ering its importance, once denudation by stent
500 implantation has occurred, its reinstatement, i.e.,
501 re-endothelialisation, is critical in order for the artery
502 to return to its normal functioning behaviour.
503 Damaged ECs, adhered platelets, VSMCs and
504 macrophages present at the injury site release mitogens
505 capable of instigating re-endothelialisation. These
506 mitogens include vascular endothelial growth factor
507 (VEGF), PDGF and bFGF and induce the ECs
508 remaining around the stent struts and outside the
509 stented area to migrate and proliferate into the
510 denuded section. In addition, increased levels of VEGF
511 circulating in the bloodstream induce precursors of
512 endothelial cell colony forming units (EC-CFUs)
513 (angiogenic monocytes and lymphocytes) and endo-
514 thelial progenitor cells (EPCs) derived from bone
515 marrow stem cells, to mobilise, enter the bloodstream
516 and home in on the injury site. It has been hypothe-
517 sised that EC-CFUs precursors arrive earlier than
518 EPCs to provide rapid coverage of the injury site and
519 secret angiogenic factors (e.g., VEGF and G-CSF)
520 which encourage EPC homing and proliferation.106
521 EPCs attach to proteins and adhesion molecules on the
522 arterial wall and subsequently differentiate into mature
523 ECs.
524 ECs or EPCs will not adhere directly to, or prolif-
525 erate over, a normal stent surface25 and as such
526 re-endothelialisation over the stent struts cannot occur
527 without an adsorbed protein layer and adhesion mol-
528 ecules expressed by cells adhered to the surface. Some
529 stent designs endeavour to promote re-endothelialisa-
530 tion by applying coatings to the stent surface.5,25,128
531 The surface texture of a stent also influences
532 re-endothelialisation and thus some new stents are
533 exploring different surface modifications which may
534 aid re-endothelialisation.6 In addition to this the sur-
535 face chemical composition also affects re-endotheliali-
536 sation, e.g., endothelial migration onto stainless steel
537 via interaction with adsorbed fibrinogen is significantly
538 greater than that observed onto gold surfaces. This
539 could be due to the surface charge, hydrophobicity, or
540 chemical composition of the surface material.133
541 Local hemodynamics at a stent implantation site
542 also have an effect on the initial and continued
543 adherence of ECs and EPCs. Large WSS oscillations
544 over positive and negative values, i.e., 1 Hz reversing
545 sinusoidal WSS of mean 20 dyne/cm2 with an ampli-
546 tude of 40 dyne/cm2, has been found to cause the
547 detachment of cultured bovine aortic ECs,58 which
548 would delay re-endothelialisation. ECs have been
549 shown to migrate downstream of an area where the
550WSSG is above 30 dyne/cm3.24,145 The migration of
551ECs into denuded areas from adjacent areas with an
552intact endothelium has been shown to be increased
553when exposed to undisturbed laminar flow as
554opposed to disturbed laminar flow or static flow.66
555Re-endothelialisation of the stent surface has also been
556found to be WSS dependent, with low WSS regions
557experiencing delayed re-endothelialisation and high
558WSS encouraging EC migration onto stent surfaces.132
559In addition to this, as the healing process progresses
560and the endothelium layer reforms, ECs can sense and
561are responsive to WSS conditions. In physiological
562flow conditions ECs align themselves in the flow
563direction and are in an atheroprotective state, releasing
564anticoagulants, antioxidants and vasodilators such as
565NO. When ECs are in regions of low WSS or high
566WSSG they switch to an atherogenic state in which
567they adopt a cobblestone shape in a more random
568arrangement, shown in Fig. 4, no longer aligned with
569the flow and presenting gaps in the endothelial layer,
570thus encouraging cellular and lipid infiltra-
571tion.110,118–120 In this form they also up-regulate
572inflammatory mediators, adhesion molecules, pro-
573coagulant and pro-thrombotic agents, and VSMC
574growth factors, all of which can lead to increased NIH
575and result in ISR.87
576The Influence of Stent Design on ISR
577There are many different stents available on the
578market with varying strut configurations, thicknesses,
579materials, and deployment mechanisms, and in the
580case of DESs different coatings, drug types, doses and
581drug release kinetics. These varying designs produce
582different degrees of structural injury, foreign-body
583reactions and hemodynamic flow field alterations,
584which in turn affect the biological processes taking
585place within the stented artery and the resultant ISR
586rates. A study by Kastrati et al.74 of 3,370 patients
587(4,229 stented lesions) who underwent angioplasty
588with stenting using different BMS types concluded that
589following vessel size, stent design was the second
590strongest factor in determining the occurrence of ISR.
591The structural injury caused by stent implantation
592to the arterial wall is assumed to be proportional to the
593stress induced within the wall, which is dependent, in
594part, upon the stent design. Self-expanding stents have
595been found to cause less injury to the endothelium than
596balloon-expandable stents, because only the stent
597struts, in contrast with both the struts and an expanded
598balloon, are in contact with the arterial wall.54 The
599injury caused by the balloon depends on the inflation
600pressure, stent geometry and distance between
601struts.117 Stent foreshortening upon expansion, elastic
602recoil,32 and deformations of the stent under flexion,155
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603 have been studied using finite element analysis and are
604 hypothesised to affect the degree of injury inflicted
605 upon the arterial wall. High stresses within the arterial
606 wall can cause increased damage, and in the case of
607 medial injury and lipid core penetration by stent struts
608 there is a propensity for increased inflammation.36 By
609 reducing the number of strut–strut intersections by one
610 third, disruption of the IEL and the media layer were
611 reduced by nearly one half in a study of steel stents
612 deployed in denuded rabbit iliac arteries.115 Several
613 clinical studies have linked the degree of arterial wall
614 prolapse between stent struts with the occurrence of
615 ISR.61,70,111 The amount of prolapse between stent
616 struts is also dependent on the strut spacing. Following
617 implantation, a stent must also be able to withstand
618 additional stresses placed upon it from vessel defor-
619 mation. In the case of coronary arteries the beating of
620 the heart causes slight movements and deformations of
621 the arteries.26–28 Also, in peripheral arteries, such as
622 the femoral, popliteal and tibial arteries, deformation
623 is caused by the flexion of the hip, knee or ankle, which
624 in some cases can cause fracture of an implanted stent
625 possibly resulting in renewed injury to the arterial wall
626 and ISR.123 Therefore, not only does the stent design
627 have an effect on the structural injury inflicted on the
628 arterial wall initially, but the properties of the stent
629 material and its ability to withstand cyclic loading of
630 the heart beating or a limb moving can also affect the
631 probability of ISR occurring during the lifetime of a
632 stent.
633 The stent material also has implications on each
634 biological process in the response to a foreign body.
635 Stainless steel, used in most BMSs, is found to oxidise
636 in the body causing varying degrees of cell toxicity.156
637 First-generation DES permanent polymer coatings
638 were found to cause delayed healing, impaired stent
639 strut endothelialisation, and hypersensitivity reactions,
640 which can culminate in stent thrombosis in some
641cases.42,72,73,103,149,151 In a study of different DESs
642implanted in rabbits by Joner et al.73 it was found that
643struts lacking endothelial coverage at 14 days showed
644focal aggregates of platelets and inflammatory cells,
645including foreign body giant cells. Therefore, in the
646absence of complete endothelialisation of polymeric
647strut surfaces increased inflammation and thrombus
648formation may result. New DES coatings such as
649phosphorycholine and the co-polymer poly(vinylidene
650fluoride-co-hexafluoropropylene) mimic the phospho-
651lipids on the outer surfaces of red blood cells.92 This
652improves the biocompatibility of the DES by masking
653its foreign nature. As a result of the observed detri-
654mental effects of permanent polymers implanted in the
655body, biodegradable polymer coatings and completely
656polymer free stents are also being developed.43
657The resultant local hemodynamics created within
658the stented lumen are also partially dependent on the
659stent design. Thrombus formation, as mentioned pre-
660viously, is heavily flow dependent with highest platelet
661deposition occurring where flow is directed towards the
662arterial wall.33 Monocyte adhesion rates were found to
663be affected by not only the local WSS, but also the
664radial component of velocity and the dynamics of the
665recirculation region and flow reattachment.112 Flow
666separation away from the arterial wall and recircula-
667tion zones occur both upstream and downstream of
668rectangular cross-sectional stent struts. Platelets within
669these zones experience long particle residence times in
670proximity to activating substances, which increases
671their probability of activation. With thinner and more
672streamlined stent struts, the recirculation zones, and
673also consequently, the particle residence times can be
674reduced.71 WSS, WSSG and WSSAG within an idea-
675lised stented artery can be predicted using computa-
676tional fluid dynamics (CFD) and different stent designs
677have been shown to produce significantly different
678distributions of each.81,82,101 The angle that stent struts
FIGURE 4. Phase-contrast monographs of confluent bovine aortic endothelial monolayers show a distinct difference between
ECs under static flow conditions (a) and those exposed to physiological WSS for 24 h (b). Reproduced and adapted with per-
mission from the Journal of Cell Science.88
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679 make with the primary direction of blood flow has been
680 shown to strongly influence the amount of intrastrut
681 area of the lumenal wall exposed to low WSS.82 Stents
682 with a greater final diameter than the implanted artery
683 not only cause increased damagewithin the arterial wall,
684 but also increase the cross-sectional area of the stented
685 artery, reducing the blood flow velocity and as a result
686 reduce the WSS within that region. Alternatively, stent
687 undersizing can result in stent strut malapposition to the
688 arterial wall, thus increasing the resistance to flow and
689 decreasing the WSS.16
690 FLOW-AUGMENTATION STENT DEVICES
691 Introduction
692 CFD analyses, in vivo and in vitro studies have been
693 used to assess the effects of stent implantation on the
694 local hemodynamics.33,34,57,80,81,101 These studies con-
695 centrate on existing stents which fulfil the basic role as
696 a scaffold to keep an artery open. Novel complemen-
697 tary devices and stent designs have been, and are cur-
698 rently being, developed which not only re-establish
699 blood-flow in an obstructed artery but establish
700 hemodynamics which inhibit ISR.
701 ARED Flow Divider
702 The Anti-Restenotic Diffuser (ARED) flow divider,
703 as shown in Fig. 5, was developed on the premise that
704 increasing the WSS in a stented artery decreases the
705 risk of developing excessive IH, resulting in ISR. The
706 device was patented by Dr Nikolaos Stergiopulos of
707 the Ecole Polytechnique Federale de Lausanne (EPFL)
708 in Switzerland in 2000 (European Patent EP0989830).
709 The concept behind the ARED flow divider is that,
710 upon insertion within the stented region, self-expand-
711 ing appendages which press against the arterial wall
712 hold a central solid cylinder along the artery’s central
713 axis. The overall cross sectional area of the artery is
714 thus reduced, as shown in Fig. 6, thereby increasing
715the blood-flow velocity close to the wall and, in turn,
716the WSS. This, in theory, reduces the extent of low
717WSS regions and hence the amount of NIH in the
718stented region.
719Wentzel et al.154 investigated the relationship
720between WSS, predicted by CFD analysis of recon-
721structed geometries approximating the lumen after
722stenting, and the observed neointimal thickening in 14
723patients at 6 month follow-up after coronary Wallstent
724implantation. An inverse relationship between in-stent
725neointimal thickening andWSS distribution in vivo was
726found. Wentzel et al.153 stated that in line with this
727work Endoart, founded by Dr Nikolaos Stergiopulos,
728developed the ARED flow divider. Carlier et al.8 pub-
729lished results which demonstrated the proof of concept
730of the ARED flow divider through the analysis of his-
731tological arterial cross sections obtained from nine New
732Zealand White rabbits implanted with just a MultiLink
733stent in one of the external iliac arteries (control seg-
734ment), and implanted with both a MultiLink stent
735along with an ARED flow divider in another. CFD was
736used to estimate the alteration of WSS in the stented
737artery due to the presence of the ARED flow divider
738using two idealised tubes: one with a centrally-located
739cylinder (approximating the segment with the ARED
740flow divider) and one without (approximating control
741segment). The increase in WSS (from 3.8 to 8.2 dyne/cm2
742as predicted by the idealised CFD analysis), caused by
743the presence of the ARED flow divider in comparison
744to the control segment, resulted in local reductions in
745injury and inflammation score, and NIH following
746stent implantation. Based on this observation, Carlier
747et al.8 concluded that this study supports the hypothesis
748that increasing the WSS within a stented region can
749lead to decreased accumulation of macrophages, pre-
750venting IEL dissolution and subsequent VSMC
751migration within that region. Histological cross sec-
752tions obtained in the study are shown in Fig. 7.
753Sanmartin et al. assessed the influence of WSS on
754ISR using a combination of angiography and intra-
755vascular ultrasound of the right coronary artery of
756seven patients following stent implantation, along with
757the results from CFD analyses of reconstructed
758geometries of the implanted arteries. In this study, an
759inverse relationship was found between WSS and NIH;
760however, it was noted that the conclusions drawn from
761the study by Carlier et al.122 should not be extrapolated
762directly to humans, given that flow conditions, vascu-
763lar geometry and response to lesions are very different
764in humans compared with rabbits.
765The ARED flow divider was never implanted in
766humans77; however, these studies demonstrate that
767local WSS distribution could influence NIH and there
768was a potential application of this fact in the design of
769new vascular devices.
FIGURE 5. ARED flow divider for insertion in a stented
artery. It is held in place by the self-expanding appendages
radiating out from the central cylinder which press against the
arterial wall.8
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770 Helical Flow Devices
771 The local hemodynamics have a significant influence
772 on the cellular activity within an arterial wall. Ath-
773 erosclerosis has been found to preferentially develop in
774 areas of disturbed flow and regions of low
775 WSS.12,14,17,79,136 Natural blood flow in the arterial
776 system has been found to be helical in nature. The
777 beneficial/detrimental implications of helical flow in
778 the cardiovascular system are open to conjecture.47
779 However, two novel stent designs are being developed
780 that endeavour to elicit helical flow and take advantage
781 of its beneficial characteristics in terms of inhibiting
782 atherosclerotic lesion development and ISR.
783 Helical Flow
784 Experiments conducted by Caro9 on the dispersion
785 of indicator flowing in simplified models of the circu-
786 latory system showed that large secondary motions
787 were induced by bends in the models. It was postulated
788 that these secondary motions had particular physio-
789 logical importance in circulation, listing possible
790 advantages as being the prevention of stagnation zones
791 and flow separation at the arterial walls. Inspired by
792 observations of spiral folds on the inner endoluminal
793 surface of arteries using fibre-optic angioscopy by
794Stonebridge and Brophy,139 postulated by Caro et al.11
795as being helical distributions of lesions due to low WSS
796zones, Stonebridge et al. went on to show that blood
797flows in the right common and distal superficial fem-
798oral and the left common femoral arteries with a sec-
799ondary rotational motion which produces an overall
800spiral (helical) flow. This was detected using Doppler
801ultrasound with the probe aligned perpendicular to the
802axial flow, as shown in Fig. 8 along with a sample
803ultrasound image.141
804The terms spiral flow and helical flow are used
805interchangeably in the literature, but for the purpose of
806this paper, helical flow is the term used. The helical
807flow in arteries is induced by their non-planar curva-
808ture and the heart itself. It has been proposed that the
809secondary motion, i.e., the rotational motion, of the
810blood flow is induced by the twisting of the left ven-
811tricle during contraction,91 and then accentuated upon
812entering the aortic arch.39,75 This twisting is, in part,
813due to the structure of the ventricular myocardial band
814of the heart which has been found by Torrent-Guasp
815to be spatially orientated in the form of a helix.147
816Brecher7 also observed that there existed a continuous
817negative pressure within the ventricle which Marinelli90
818cited as evidence of a perpetual vortex within the
819ventricle, which provides the ventricular suction during
FIGURE 6. (a) and (b) Diagrams taken from European Patent EP0989830 (B1) showing the axial velocity distribution across an
idealised artery before (a) and after implantation (b) of an ARED flow divider. The central cylinder is marked 1 above in (b) and the
arterial wall is marked 2 in both diagrams. The axial velocity distribution is a function of the radius, r, with ri representing the outer
radius of the cylinder and ro representing the inner radius of the artery.
134
FIGURE 7. Histological cross-sections taken from a stented arterial segment with (a) and without the flow divider (b). Reduced
NIH is clearly observed in the region with the flow divider present.8
MURPHY AND BOYLE
Journal : CVET MS Code : 13239 PIPS No. : 109 h TYPESET h DISK h LE h CP Dispatch : 1-10-2012 Pages : 214 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
820 the diastolic period, and possibly incites the initial
821 helical flow. Helical flow had been observed before in
822 the human aorta by Segadel and Matre125 and again by
823 Kilner and Guang75 using magnetic resonance imaging
824 (MRI), and by Frazin et al.39 in canine thoracic and
825 abdominal aortae using Doppler ultrasound, but the
826 studies by Stonebridge et al. were the first to show that
827 the helical flow was maintained in the peripheral
828 arteries also. Suo143 concluded, following MRI and
829 CFD analysis, that helical flow in the aorta could only
830 be produced by including the specific aortic motion
831 caused by the beating heart. Caro et al.11 published
832 observations from MRI data of flow through healthy
833 human arteries with non-planar curvature and
834 branching which showed how these features appeared
835 to significantly affect the hemodynamics, including
836 WSS.
837 Many of the beneficial effects of helical flow in the
838 arteries were originally only postulations by
839 researchers in the area; however, there is growing evi-
840 dence which support these postulations. Stonebridge
841 et al.141 discuss how there are theoretical advantages to
842 helical flow, including rotationally-induced stability,
843 reduced turbulence, and a beneficial effect on mecha-
844 nisms of endothelial damage. A paper by Caro et al.11
845 it was highlighted that greater mixing and more uni-
846 form WSS was expected in the cardiovascular system
847 which was found to be commonly non-planar. Doorly
848 et al.29 found through CFD analysis that a simple
849 modification to the geometry of an end-to-side anas-
850 tomosis, where the graft is rendered approximately
851 helical, produced a profound effect on the flow,
852 enhancing the swirling motion of the flow downstream.
853 Zabielski and Mestel157 concluded from a CFD anal-
854 ysis into helical flow around arterial bends that the
855 non-planar curvature limits the severity of flow sepa-
856 ration at the inner bend and reduces variation of the
857 WSS. This was confirmed in a CFD analysis by
858 Papaharilaou et al.108 of planar and non-planar
859end-to-side anastomoses where it was found that the
860introduction of an out-of-plane curvature produced a
861significant change in the spatial distribution of WSS
862and a 10% reduction in the time-averaged peak WSS
863magnitude. The spatial extent of the elevated oscilla-
864tory WSS regions was reduced in the non-planar model
865in comparison with the planar model and given that
866Ku et al.79 found a correlation between elevated
867oscillatory WSS and NIH there are effectively less
868areas exposed to unfavourable, in terms of disease
869progression or ISR, flow conditions in the non-planar
870geometry. In a numerical study of vortical flow iden-
871tification and flow transport in arterial graft geome-
872tries, Doorly et al.30 found that significant greater
873particle mixing was prevalent in the non-planar
874geometry compared with the planar geometry, with
875continual transport of particles away from the wall,
876thus lessening near-wall particle residence times.
877Stonebridge et al.140 compared helical and non-helical
878flow patterns through stenoses using MRI in vitro and
879CFD modelling. In this study it was found that near-
880wall turbulence energy was up to 700% less with
881helical flow than non-helical flow beyond the stenosis,
882with turbulence being associated with substantial WSS
883fluctuations in both space and time.89 The degree of
884helical flow has been found by Houston et al.63 to be
885reduced in atherosclerotic arteries, although a direct
886relationship between atherosclerotic lesions and the
887absence of helical flow has not been proven, and within
888these arteries the turbulent nature of the resulting flow
889encourages further development of the disease. A study
890by Morbiducci et al.98 indicated that helical flow
891dampened WSS temporal gradients in aortocoronary
892bypass grafts. Morbiducci et al.100 also conducted an
893in vivo investigation into the helical flow patterns in the
894aortic region of five healthy humans using 4D phase-
895contrast MRI, and CFD analyses of the reconstructed
896aortic geometries. It was found that helical-blood-flow
897dynamics is common to healthy individuals, and that
FIGURE 8. (a) The Doppler ultrasound set up used in the experiment described by Stonebridge et al.141 (b) This sample image
clearly shows the characteristic red/blue split signifying helical flow as observed in vivo.138 Reproduced with permission from
Vascular Flow Technologies.
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898 helical flow might be caused by natural optimisation of
899 fluid transport processes in the cardiovascular system,
900 aimed at obtaining efficient perfusion of blood and
901 nutrients therein to the organs and tissue. In predicting
902 these transport processes, and also those involved in
903 atherogenesis, a paper by Chiastra et al.18 highlighted
904 that flow properties such as velocity, helicity and vor-
905 ticity are primarily responsible, and that researchers
906 should consider these bulk flow properties in addition
907 to the WSS variables. Liu et al.86 conducted a CFD
908 study of the transport of low density lipoprotein
909 (LDL) in four models of human aortae and found that
910 the helical flow induced in the aortic arch had a ben-
911 eficial effect on LDL concentration at the arterial wall.
912 Helical flow has also been shown to be instrumental in
913 moderating shear-induced activation of platelets,
914 which is a problem for some cardiovascular
915 implants.93,99,158 Massai et al.93 found through CFD
916 simulations of a reconstructed model of a left carotid
917 bifurcation that an inverse relationship existed between
918 the helical flow index (variable for measuring the
919 helical structure of the flow) and the probability of
920 shear-induced activation of platelets.
921 An analysis by Paul and Larman109 using CFD of
922 helical flow downstream of a 75% stenosis found that
923 turbulent kinetic energy was reduced post stenosis. The
924 helical motion provides rotational stability to the flow,
925 reducing flow disturbance and turbulence, which is a
926 beneficial effect. Conversely, as noted by Paul and
927 Larman,109 helical flow also produced oscillating WSS
928 in the post-stenosis model, which is considered a det-
929 rimental effect possibly causing damage to the endo-
930 thelium. In addition to this, other researchers have
931 speculated on whether the effects of helical flow are
932 entirely beneficial. Frazin et al.38 considered that
933 although the rotational element of the flow may be
934 important physiologically for organ perfusion, patho-
935 logically, there may be a relation between the shear
936 forces induced by helical flow and plaque deposition. A
937 paper by Texon146 showed that ‘‘serpentine flow’’ in
938 relatively straight vessels may also produce zones of
939 diminished lateral pressure and atherosclerosis. A
940 CFD study of helical grafts by Zheng et al.159 found
941 that along with the benefits of increased WSS and
942 swirling flow, there was also an enlarged pressure drop
943 and low velocity concentrated in one area in a helical
944 graft model which could lead to increased NIH or
945 thrombosis. Pressure drop was found to be propor-
946 tional to the helicity of an inlet flow into an idealised
947 stented artery in a CFD study by Chen et al.15 CFD
948 simulations conducted in this study showed pressure
949 drops for the stent with swirling flow to be 164, 167
950 and 173 Pa for inlet helicities of 3.5, 6.4 and 14.5 m/s2,
951 respectively, whereas for the stent with normal inlet
952 flow the pressure drop was 163 Pa. Beneficial effects of
953helical flow also noted in this paper were that the
954average lengths of the recirculation zones between the
955stent struts and oscillatory shear index (OSI), a mea-
956sure of the change in direction and magnitude of the
957WSS vectors during the cardiac cycle, were reduced
958with increasing helicity of the inlet flow, which
959enhanced the average WSS in comparison with normal
960flow.15
961Considering the correlation between adverse flow
962conditions and increased NIH3,45,55,59,76,107 and the
963effects of the local hemodynamics on the other bio-
964logical processes leading to ISR, discussed in ‘‘In-Stent
965Resteno’’ section, there are two particular stents which
966are embracing the beneficial effects of helical flow, i.e.,
967increasing particle mixing, reducing areas of disturbed
968flow and providing a more uniform WSS, and
969endeavour to restore this natural blood flow pattern in
970a stented artery.
971BioMimics 3D Helical Stent
972The BioMimics 3D helical stent is being developed
973by Veryan Medical Ltd which has its head office in
974Horsham, West Sussex, UK and research and
975development based in Galway, Ireland. This stent
976appears to have evolved from a helical bypass graft,
977marketed as SwirlGraft, which incorporated Small
978Amplitude Helical Technology (SMAHT), developed
979at Imperial College London. The theory behind this
980technology is that a normal planar bend induces two
981equal but opposite Dean vortices within the flow,
982whereas in a non-planar bend, as found in SMAHT,
983one of the vortices begins to dominate the other as
984the flow progresses through the bend, producing
985helical flow. Caro et al.10 compared SwirlGraft
986devices with conventional expanded polytetrafluor-
987ethylene (ePTFE) arteriovenous shunts in two pigs.
988Even though the experiment was limited by the
989number of pigs employed, the results of this study
990were still positive with consistently less thrombus
991formation and NIH in SwirlGraft devices compared
992with the conventional devices. Interestingly, when the
993porcine arterial sections were analysed, two seemingly
994helical ribbons of NIH were found which seemed to
995match with the predicted areas of low WSS in a CFD
996model of SwirlGraft. A clinical trial was carried out
997by Huijbregts et al.67 in which 20 patients requiring
998vascular access grafts were implanted with Swirl-
999Graft. It was found that the graft was prone to
1000thrombosis, possibly due to the loss of the helical
1001geometry of the graft upon implantation. It was
1002concluded by Huijbregts et al.67 that with modifica-
1003tions to implantation techniques and the SwirlGraft
1004design that the product might advance to a ran-
1005domised controlled trial.
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1006 Veryan Medical has taken this same SMAHT
1007 technology and applied it to peripheral stent design in
1008 the form of the BioMimics 3D helical stent, shown in
1009 Fig. 9, possibly with the aim of entering into the
1010 broader stent market once the technology has been
1011 proven. In addition to the helical flow benefits, the
1012 stent also includes design features such as tapered
1013 radial stiffness and collinear stent ends which, in the-
1014 ory, help in providing a more gradual change in the
1015 wall stress and lumenal area between the unstented and
1016 stented portion of the artery, as opposed to a dramatic
1017 change which could form a stagnation zone in the flow,
1018 encouraging thrombus and neointimal formation. For
1019 peripheral stent implantation, in the femoral artery
1020 particularly, as the leg bends the stent must be flexible
1021 enough to allow movement and longitudinal slacken-
1022 ing of the artery without stent fracture or the infliction
1023 of damage on the arterial wall. The BioMimics 3D
1024 helical stent has been assessed in this regard through a
1025 human cadaver study as stated on the company web-
1026 site (http://www.veryanmed.com/). In this study the
1027 BioMimics 3D stent and control straight stents were
1028 implanted in the lower and mid superficial femoral
1029 artery and the upper popliteal fossa of three cadavers
1030 and the knee joint was flexed over a range of angles. It
1031 was observed that the BioMimics 3D helical stent
1032 could increase its helicity and thus take up the slack in
1033 the artery upon flexion of the knee, while also avoiding
1034 permanent deformation, unlike the straight stents. This
1035 ability is deemed a valuable characteristic which could
1036 prolong the life of a peripheral stent by absorbing
1037 stresses which ordinarily could cause fracture.
1038 As mentioned earlier, studies by Lee et al.83 into the
1039 effects of supplemental oxygen on NIH and by
1040 Tarbell144 into mass transport of molecules, e.g., oxy-
1041 gen, into arterial walls and localisation of atheroscle-
1042 rosis and NIH, highlight the importance of flow
1043 conditions and oxygen flux into the arterial wall on the
1044 development of NIH. Coppola and Caro,21 citing
1045 Tarbell and the link between a local lack of oxygen and
1046 both atherosclerosis and NIH, used CFD to examine
1047the effects of arterial three-dimensionality on the dis-
1048tribution of WSS a the mass transport of oxygen from
1049the blood flow into the arterial wall in a U-bend by
1050modelling the blood vessels as either a cylindrical or
1051helical conduit. It was shown that a helical geometry
1052can reduce both the range and extent of low WSS
1053regions and substantially increase the oxygen flux
1054through the walls.
1055Shinke et al.130 presented results from a pilot por-
1056cine trial where two pigs were implanted with a con-
1057ventional stent in one common carotid artery and the
1058BioMimics 3D helical stent in the contralateral artery,
1059as shown in the angiograph in Fig. 10. Comparisons
1060were made between the histological sections taken at
1061three locations in the two arteries, as shown in Fig. 11.
1062As can be seen from these sections the extent of NIH
1063with the helical stent was far less than with the con-
1064ventional one and thus it was concluded that the
1065helical stent’s improved flow regime helped in mini-
1066mising NIH.
1067The in vivo results from this porcine study were
1068compared with CFD predictions by Coppola and
1069Caro22 and the effects of varying the geometrical
1070parameters, i.e., the amplitude and frequency of the
1071helical shape, on the flow pattern, WSS, and oxygen
1072flux to the arterial wall were studied. It was expected that
1073the increased mixing effects of the geometry-induced
1074secondary flows would modify the distribution of WSS
1075and produce higher oxygen flux levels to the arterial
1076wall. Results showed that increasing the amplitude of
1077the helical geometry increased theWSS and oxygen flux
1078to the vessel wall, and that increasing the frequency
1079increased theWSSbut hadno effect on the oxygenflux.22
1080Oddly, the results indicated that the inner curvature
FIGURE 9. BioMimics 3D helical stent. Reproduced with
permission from Veryan Medical Ltd.
FIGURE 10. Angiograph showing the BioMimics 3D helical
stent and the conventional straight stent inserted in the con-
tralateral (left) and common carotid artery (right) respec-
tively.130 Reproduced with permission from Veryan Medical
Ltd.
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1081 regions of the helical model are exposed to lower oxygen
1082 flux than in the corresponding straight stent case, and
1083 yet the development of NIH is lower in these regions, as
1084 shown by the porcine trial. The reasons for this were
1085 inconclusive; however, the overall results of the study
1086 were positive.
1087 Cookson et al.20 conducted a CFD investigation of
1088 the mixing behaviour of a small amplitude helical pipe
1089 incorporating two different helical geometries, as
1090 shown in Fig. 12. Helix A has an amplitude of 0.2
1091 times the diameter of the pipe and Helix B has an
1092 amplitude of 0.5 times the diameter. This investigation
1093 was based on the hypothesis that increased mixing,
1094 induced by helical geometries, reduced thrombosis in
1095 grafts incorporating SMAHT and that by joining
1096 together two helical geometries of different amplitudes
1097 the mixing effect could be enhanced further without an
1098 excessive pressure loss across the device. This study fol-
1099 lowed on from a previous numerical study of single
1100 helical geometries by Cookson et al.19 The results of the
1101 investigation indicated that the mixing effect was
1102 improved upon in the combined helical geometry in
1103 comparison with the single helical geometry and that the
1104 pressure drop was found to be less in the combined
1105 helical geometry. These results show a possible
1106 improvement in the original SMAHT design on which
1107 SwirlGraft and theBioMimics 3Dhelical stent are based.
1108Vascular Flow Technologies Ltd. Stent
1109The BioMimics 3D helical stent induces a helical
1110flow by imposing a helical geometry on the treated
1111artery, while another stent technology, currently in
1112development at Vascular Flow Technologies Ltd
1113(VFT) based in Dundee, Scotland, induces helical flow
1114through the use of a helical ridge placed on the inner
1115surface of the stent. VFT (formerly Tayside Flow
1116Technologies) is a spin-out company set up in 1998
1117from Tayside University Hospitals NHS Trust. The
1118stent technology being developed by VFT is based on
1119research by Stonebridge et al.139–141 into the naturally
1120occurring helical flow found in studies of the cardio-
1121vascular system using Doppler ultrasound, as men-
1122tioned previously. The benefits of helical flow,
1123discussed earlier, led VFT to design a bypass graft,
FIGURE 11. Histological sections of the stented arteries one month post implantation. The conventional straight stent is shown
in (a) and the BioMimics 3D helical stent in (b). (i), (ii) and (iii) correspond to locations proximal, middle and distal to the stented
sections respectively.130 Reproduced with permission from Veryan Medical Ltd.
FIGURE 12. Diagram of the helical geometry employed by
Cookson et al.20 in a CFD analysis of the mixing behaviour in a
helical pipe with two different helical geometries.
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1124 which was similar to SwirlGraft in its goal is to induce
1125 helical flow; however, instead of shaping the graft in a
1126 helical form which could be lost on implantation, this
1127 bypass graft incorporated a helical ridge at the distal
1128 end of the graft, which restored helical flow. Early
1129 clinical results from a first-in-man study were pre-
1130 sented by Vermassen and Stonebridge150 in which 40
1131 patients with peripheral arterial disease had the graft
1132 implanted. 10 patients were assessed for the presence of
1133 helical flow at 6 months and in all 10 helical flow was
1134 evident, confirming that the graft induced helical flow.
1135 In addition, a patency-rate of 88% at 1 year follow-up
1136 was found for the 40 patients treated.150
1137 The company is currently developing a helical-ridge
1138 insert for stents, similar to the graft design, in order to
1139 induce helical flow in a stented artery. Two patents
1140 which have been filed give some details of this tech-
1141 nology: European Patent EP1314406 (B1)65 and US
1142 Patent US7721767 (B2).64 The former describes a
1143 partially helical-shaped ridge insert for a stent as
1144 shown in Fig. 13, while the latter gives details of a
1145 method for determining the helix angle of a helical
1146 formation for a conduit.
1147 A conduit, as described in the US Patent, includes
1148 natural blood-flow tubing, stents, and artificial indus-
1149 trial equipment, e.g., a hose or pipe.64 The method
1150 described in this patent allows the determination of the
1151 optimum helix angle through the use of two charac-
1152 teristic curves. As shown in Fig. 14, for a given mass
1153 flow rate in a given conduit the experimentally deter-
1154 mined non-dimensional pressure drop and turbulent
1155 kinetic energy are plotted against the helix angle. The
1156 optimum helix angle would normally correspond to the
1157 angle at which the non-dimensional pressure drop and
1158 the non-dimensional turbulent kinetic energy are equal
1159 to zero, in this case at approximately 7.5 degrees
1160 (notated as 52 in Fig. 14); however, this may not
1161 always be the case.64
1162 In a preclinical porcine study by Houston et al.,62 an
1163 unmodified control stent and a modified stent incor-
1164 porating the helical-ridge insert were compared in a
1165 45 day carotid cuff stenosis model. The cuff model is
1166designed to mimic lesions that may occur downstream
1167of a stent and to induce cell proliferation and ECM
1168synthesis, both of which contribute to neointimal
1169thickening. There was a statistically significant reduc-
1170tion in intima/media ratios distal to the implanted
1171region in the modified stent porcine models, with a
1172high ratio indicating significant neointimal thickening,
1173in comparison with the control stent porcine models.
1174Using Doppler ultrasound it was confirmed that the
1175modified stent maintained the natural helical flow
1176within the arteries of all eight pigs, whereas, the control
1177stent did not. An idealised plain-wall tube was com-
1178pared with a tube with a helical ridge using CFD and
1179results obtained predicted a reduction in turbulent
1180kinetic energy downstream of a 50% stenosis in the
1181helical-ridge model.
1182DISCUSSION
1183There are many factors which influence the biological
1184processes that can result in ISR.The local hemodynamics
FIGURE 13. Axial and longitudinal views of the proposed helical-ridge insert for stents, adapted from European Patent
EP1314406 (B1).65
FIGURE 14. Graph taken from US Patent US7721767. The
variation of non-dimensional pressure drop with the helix
angle is notated as 50 and the variation of non-dimensional
turbulent kinetic energy with the helix angle is notated as 51.
The helix angle when both variables are equal to zero is
notated as 52.64
Reducing In-Stent Restenosis
Journal : CVET MS Code : 13239 PIPS No. : 109 h TYPESET h DISK h LE h CP Dispatch : 1-10-2012 Pages : 214 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
1185 is one of the factors that can be controlled to some degree
1186 by stent design. The ARED flow divider demonstrated
1187 that by increasing the blood flow velocitywithin a stented
1188 region, NIH could be reduced. Helical flow has been
1189 shown to exist in healthy arteries, although its implica-
1190 tions within the cardiovascular system are currently not
1191 fully understood. Through human, animal, in vitro and
1192 CFD studies helical flow has been shown to have bene-
1193 ficial hemodynamic characteristics in terms of inhibiting
1194 thrombus formation, inflammation and NIH in vascular
1195 grafts. Helical-flow-inducing technology is now being
1196 transferred over to the stent market to help reduce ISR
1197 rates. The theoretical benefits of this technology com-
1198 pared with current stent designs are greater mixing of
1199 particle trajectories, increased rotationally-induced sta-
1200 bility, and reduced turbulence, stagnation zones, lengths
1201 of recirculation zones and near-wall particle residence
1202 times.Helical flowhasalsobeen shown to reduceboth the
1203 range and extent of low WSS regions and substantially
1204 increase the oxygen flux through the arterial walls which
1205 could help minimise NIH. Both OSI and low WSS have
1206 been implicated in increased NIH and the hindering of
1207 re-endothelialisation. Helical flow has the benefit of
1208 reducing OSI and increasing the average WSS within the
1209 stented region. With these beneficial hemodynamic
1210 characteristics and their recognised effects on the bio-
1211 logical processes post stent implantation, ISR rates could
1212 be reduced.
1213 Some concerns highlighted with helical flow were an
1214 increase in pressure drop across a segment with helical
1215 flow compared with normal flow and low flow velocity
1216 concentrated in one area. One other issue is the
1217 mechanical stress levels imposed on an implanted artery
1218 which directly affect the amount of injury inflicted on the
1219 arterial wall. This is a concern for both helical-flow-
1220 inducing devices presented in this paper. TheBioMimics
1221 3Dhelical stent can impose a severe geometric change on
1222 an artery and thus, could cause more damage to the
1223 arterial wall than a contemporary stent which conforms
1224 to the implanted artery. This issue has been addressed to
1225 an extent with tapered radial stiffness and collinear stent
1226 ends. TheVFT helical-ridge insert could also have issues
1227 with stiffening of the stent caused by the ridge insert.
1228 This depends on the properties of the insert material and
1229 the manner in which it is fixed to the stent platform. To
1230 the best of the authors’ knowledge there is no informa-
1231 tion available in the literature on the stress levels
1232 imposed by either designs and this could be an avenue
1233 for further study.
1234 Clearly, more research into the nature of blood flow
1235 which occurs naturally in healthy arteries and ways to
1236 imitate it is needed, and at present is certainly gain-
1237 ing interest. Both helical stent technologies, which
1238 through the principles of biomimicry embrace the
1239natural geometrical characteristics of the vascular
1240system, are promising in the goal of reducing NIH. The
1241BioMimics 3D helical stent itself is initially being tar-
1242geted at the peripheral stent market. Veryan Medical
1243have commenced a first-in-human and CE mark study
1244at Herz Zentrum in Bad Krozingen, Germany under
1245Professor Thomas Zeller. The VFT helical-ridge insert
1246is still in development, is described as being potentially
1247complimentary to DES technology, and is initially
1248targeted at the peripheral stent market, with an
1249expected date for securing the CE mark and FDA
1250approval during the third quarter of 2012.104
1251CONCLUSION
1252In an editorial by Richter and Edelman,113 the
1253argument is presented that cardiology is flow. From
1254inception, the cardiovascular system, and in particular
1255the heart, develops in form and function as a flow
1256system governed by blood-flow characteristics. This
1257system is then continually modified according to the
1258flow demands placed upon it throughout the body.
1259Given that atherosclerosis, a disease affecting this flow
1260system, has been proven to be initiated by endothelial
1261dysfunction in areas of flow disturbance, the idea of
1262the end goal of angioplasty being simply the displace-
1263ment of a lesion and the re-establishment of flow might
1264not be enough. The novel devices presented here look
1265beyond this and concentrate on encouraging beneficial
1266flow which can use the arterial-wall cells’ natural
1267responses to hemodynamics to aid in the healing of the
1268stented region, potentially reducing ISR rates.
9
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